Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Equal Management of Equal Risks: What Should be Used as the Standard for Cervical Cancer Prevention?

Kinney WK, Perkins RB, Sawaya GF.

J Low Genit Tract Dis. 2018 Jul;22(3):237-241. doi: 10.1097/LGT.0000000000000402. No abstract available.

2.

Low Risk of Cervical Cancer/Precancer Among Most Women Under Surveillance Postcolposcopy.

Demarco M, Cheung LC, Kinney WK, Wentzensen N, Lorey TS, Fetterman B, Poitras NE, Befano B, Castle PE, Schiffman M.

J Low Genit Tract Dis. 2018 Apr;22(2):97-103. doi: 10.1097/LGT.0000000000000382.

3.

Clinical Outcomes after Conservative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in Women Ages 21-39 Years.

Silver MI, Gage JC, Schiffman M, Fetterman B, Poitras NE, Lorey T, Cheung LC, Katki HA, Locke A, Kinney WK, Castle PE.

Cancer Prev Res (Phila). 2018 Mar;11(3):165-170. doi: 10.1158/1940-6207.CAPR-17-0293. Epub 2018 Feb 5.

PMID:
29437696
4.

Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer.

Clarke MA, Fetterman B, Cheung LC, Wentzensen N, Gage JC, Katki HA, Befano B, Demarco M, Schussler J, Kinney WK, Raine-Bennett TR, Lorey TS, Poitras NE, Castle PE, Schiffman M.

J Clin Oncol. 2018 Apr 20;36(12):1184-1191. doi: 10.1200/JCO.2017.75.3442. Epub 2018 Jan 22.

PMID:
29356609
5.

Adherence patterns to extended cervical screening intervals in women undergoing human papillomavirus (HPV) and cytology cotesting.

Rendle KA, Schiffman M, Cheung LC, Kinney WK, Fetterman B, Poitras NE, Lorey T, Castle PE.

Prev Med. 2018 Apr;109:44-50. doi: 10.1016/j.ypmed.2017.12.023. Epub 2017 Dec 27.

PMID:
29288782
6.

Challenges in risk estimation using routinely collected clinical data: The example of estimating cervical cancer risks from electronic health-records.

Landy R, Cheung LC, Schiffman M, Gage JC, Hyun N, Wentzensen N, Kinney WK, Castle PE, Fetterman B, Poitras NE, Lorey T, Sasieni PD, Katki HA.

Prev Med. 2018 Jun;111:429-435. doi: 10.1016/j.ypmed.2017.12.004. Epub 2017 Dec 6.

7.

Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer: An Observational Cohort Study.

Castle PE, Kinney WK, Xue X, Cheung LC, Gage JC, Zhao FH, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Katki HA, Schiffman M.

Ann Intern Med. 2018 Jan 2;168(1):20-29. doi: 10.7326/M17-1609. Epub 2017 Nov 28.

PMID:
29181509
8.

Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.

Schiffman M, Kinney WK, Cheung LC, Gage JC, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Befano B, Schussler J, Katki HA, Castle PE.

J Natl Cancer Inst. 2018 May 1;110(5):501-508. doi: 10.1093/jnci/djx225.

PMID:
29145648
9.

Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines.

Demarco M, Lorey TS, Fetterman B, Cheung LC, Guido RS, Wentzensen N, Kinney WK, Poitras NE, Befano B, Castle PE, Schiffman M.

J Low Genit Tract Dis. 2017 Oct;21(4):261-267. doi: 10.1097/LGT.0000000000000343.

10.

Why does cervical cancer occur in a state-of-the-art screening program?

Castle PE, Kinney WK, Cheung LC, Gage JC, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Befano B, Schussler J, Katki HA, Schiffman M.

Gynecol Oncol. 2017 Sep;146(3):546-553. doi: 10.1016/j.ygyno.2017.06.003. Epub 2017 Jun 10.

PMID:
28606721
11.
12.

The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen.

Silver MI, Schiffman M, Fetterman B, Poitras NE, Gage JC, Wentzensen N, Lorey T, Kinney WK, Castle PE.

Cancer. 2016 Dec 1;122(23):3682-3686. doi: 10.1002/cncr.30277. Epub 2016 Sep 22.

13.

Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.

Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, Kinney WK, Massad LS, Mayeaux EJ, Saslow D, Schiffman M, Wentzensen N, Lawson HW, Einstein MH.

Gynecol Oncol. 2015 Feb;136(2):178-82. doi: 10.1016/j.ygyno.2014.12.022. Epub 2015 Jan 8.

PMID:
25579107
14.

Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.

Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, Kinney WK, Massad LS, Mayeaux EJ, Saslow D, Schiffman M, Wentzensen N, Lawson HW, Einstein MH.

J Low Genit Tract Dis. 2015 Apr;19(2):91-6. doi: 10.1097/LGT.0000000000000103.

PMID:
25574659
15.

Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.

Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, Kinney WK, Massad LS, Mayeaux EJ, Saslow D, Schiffman M, Wentzensen N, Lawson HW, Einstein MH.

Obstet Gynecol. 2015 Feb;125(2):330-7. doi: 10.1097/AOG.0000000000000669.

PMID:
25569009
16.

Response.

Gage JC, Schiffman M, Katki HA, Castle PE, Fetterman B, Wentzensen N, Poitras NE, Lorey T, Cheung LC, Kinney WK.

J Natl Cancer Inst. 2014 Dec 26;107(1):390. doi: 10.1093/jnci/dju390. Print 2015 Jan. No abstract available.

17.

Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection.

Gage JC, Katki HA, Schiffman M, Fetterman B, Poitras NE, Lorey T, Cheung LC, Castle PE, Kinney WK.

Int J Cancer. 2015 Apr 1;136(7):1665-71. doi: 10.1002/ijc.29143. Epub 2014 Sep 2.

18.

The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management.

Gage JC, Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Behrens C, Sharma A, Zhao FH, Cuzick J, Yang ZH, Kinney WK.

Cancer Cytopathol. 2014 Nov;122(11):842-50. doi: 10.1002/cncy.21463. Epub 2014 Jul 9.

19.

Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.

Gage JC, Schiffman M, Katki HA, Castle PE, Fetterman B, Wentzensen N, Poitras NE, Lorey T, Cheung LC, Kinney WK.

J Natl Cancer Inst. 2014 Jul 18;106(8). pii: dju153. doi: 10.1093/jnci/dju153. Print 2014 Aug.

20.

2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors.

Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, Solomon D, Wentzensen N, Lawson HW; 2012 ASCCP Consensus Guidelines Conference.

Obstet Gynecol. 2013 Apr;121(4):829-46. doi: 10.1097/AOG.0b013e3182883a34.

PMID:
23635684
21.

Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S78-84. doi: 10.1097/LGT.0b013e31828543c5.

22.

Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less.

Katki HA, Gage JC, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S69-77. doi: 10.1097/LGT.0b013e31828543b1.

23.

Five-year risk of CIN 3+ to guide the management of women aged 21 to 24 years.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S64-8. doi: 10.1097/LGT.0b013e3182854399.

24.

Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S56-63. doi: 10.1097/LGT.0b013e318285437b.

25.

Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S50-5. doi: 10.1097/LGT.0b013e3182854282.

26.

Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S43-9. doi: 10.1097/LGT.0b013e3182854269.

27.

Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S36-42. doi: 10.1097/LGT.0b013e3182854253.

28.

Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S28-35. doi: 10.1097/LGT.0b013e318285423c.

29.

2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors.

Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, Solomon D, Wentzensen N, Lawson HW; 2012 ASCCP Consensus Guidelines Conference.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S1-S27. doi: 10.1097/LGT.0b013e318287d329. Erratum in: J Low Genit Tract Dis. 2013 Jul;17(3):367.

PMID:
23519301
30.

Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.

Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, Demuth F, Schiffman M, Wacholder S, Castle PE.

Lancet Oncol. 2011 Jul;12(7):663-72. doi: 10.1016/S1470-2045(11)70145-0. Epub 2011 Jun 16. Erratum in: Lancet Oncol. 2011 Aug;12(8):722.

31.

Chemoradiation for primary invasive squamous carcinoma of the vagina.

Dalrymple JL, Russell AH, Lee SW, Scudder SA, Leiserowitz GS, Kinney WK, Smith LH.

Int J Gynecol Cancer. 2004 Jan-Feb;14(1):110-7.

PMID:
14764038
32.

Risk of occult inguinofemoral lymph node metastasis from squamous carcinoma of the vulva.

Gonzalez Bosquet J, Kinney WK, Russell AH, Gaffey TA, Magrina JF, Podratz KC.

Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):419-24.

PMID:
12957253
33.

Whole abdomen radiotherapy for patients with peritoneal dissemination of endometrial adenocarcinoma.

Lee SW, Russell AH, Kinney WK.

Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):788-92.

PMID:
12788186
34.

Atypical glandular cells of undetermined significance (AGUS): cytopathologic features, histopathologic results, and human papillomavirus DNA detection.

Ronnett BM, Manos MM, Ransley JE, Fetterman BJ, Kinney WK, Hurley LB, Ngai JS, Kurman RJ, Sherman ME.

Hum Pathol. 1999 Jul;30(7):816-25.

PMID:
10414501
35.

Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.

Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, Ransley JE, Fetterman BJ, Hartinger JS, McIntosh KM, Pawlick GF, Hiatt RA.

JAMA. 1999 May 5;281(17):1605-10.

PMID:
10235153
36.

Where's the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses.

Kinney WK, Manos MM, Hurley LB, Ransley JE.

Obstet Gynecol. 1998 Jun;91(6):973-6.

PMID:
9611007
37.

Prophylactic chemoradiation of inguinofemoral lymph nodes in patients with locally extensive vulvar cancer.

Leiserowitz GS, Russell AH, Kinney WK, Smith LH, Taylor MH, Scudder SA.

Gynecol Oncol. 1997 Sep;66(3):509-14.

PMID:
9299268
38.

Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration.

Morris M, Alvarez RD, Kinney WK, Wilson TO.

Gynecol Oncol. 1996 Feb;60(2):288-91.

PMID:
8631553
39.

Surgical treatment of patients with stages IB and IIA carcinoma of the cervix and palpably positive pelvic lymph nodes.

Kinney WK, Hodge DO, Egorshin EV, Ballard DJ, Podratz KC.

Gynecol Oncol. 1995 May;57(2):145-9.

PMID:
7729726
40.
41.

A matched study of surgically treated stage IB adenosquamous carcinoma and adenocarcinoma of the uterine cervix.

Helm CW, Kinney WK, Keeney G, Lawrence WD, Frank TS, Gore H, Reynolds RK, Soong SJ, Partridge EE, Roberts J, Podratz K, Shingleton HM.

Int J Gynecol Cancer. 1993 Jul;3(4):245-249.

42.

Condylomata acuminata. Roles of different techniques of laser vaporization.

Townsend DE, Smith LH, Kinney WK.

J Reprod Med. 1993 May;38(5):362-4.

PMID:
8320672
43.

Second-look operation in ovarian cancer.

Podratz KC, Kinney WK.

Cancer. 1993 Feb 15;71(4 Suppl):1551-8. Review.

PMID:
8431893
44.

Synchronous radiation and cytotoxic chemotherapy for locally advanced or recurrent squamous cancer of the vulva.

Russell AH, Mesic JB, Scudder SA, Rosenberg PJ, Smith LH, Kinney WK, Townsend DE, Trelford JD, Taylor MH, Zukowski CL, et al.

Gynecol Oncol. 1992 Oct;47(1):14-20.

PMID:
1427394
45.

Flow-cytometric DNA analysis of stages IB and IIA cervical carcinoma.

Zanetta GM, Katzmann JA, Keeney GL, Kinney WK, Cha SS, Podratz KC.

Gynecol Oncol. 1992 Jul;46(1):13-9.

PMID:
1634134
46.
47.

Identification of prognostic factors and risk groups in patients found to have nodal metastasis at the time of radical hysterectomy for early-stage squamous carcinoma of the cervix.

Alvarez RD, Soong SJ, Kinney WK, Reid GC, Schray MF, Podratz KC, Morley GW, Shingleton HM.

Gynecol Oncol. 1989 Nov;35(2):130-5.

48.

Value of adjuvant whole-pelvis irradiation after Wertheim hysterectomy for early-stage squamous carcinoma of the cervix with pelvic nodal metastasis: a matched-control study.

Kinney WK, Alvarez RD, Reid GC, Schray MF, Soong SJ, Morley GW, Podratz KC, Shingleton HM.

Gynecol Oncol. 1989 Sep;34(3):258-62.

49.

Wertheim hysterectomy in the geriatric population.

Kinney WK, Egorshin EV, Podratz KC.

Gynecol Oncol. 1988 Sep;31(1):227-32.

PMID:
3410351

Supplemental Content

Loading ...
Support Center